2017 American Transplant Congress » Poster Session D: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Date: Tuesday, May 2, 2017

Time: 6:00pm-7:00pm

Location: Hall D1

Session Type: Poster Session

Meeting: 2017 American Transplant Congress

6:00pm-7:00pm: A Critical Analysis of Equations for MPA Exposure in Patients Under EC-MPS and Tacrolimus.

E. David-Neto, A. Triboni, F. Ramos, F. Agena, P. Romano, G. Freitas.

6:00pm-7:00pm: A Novel Endpoint for Evaluating the Effect of Everolimus with Reduced Calcineurin Inhibitor on Long-Term Kidney Graft Outcome: The TRANSFORM Study Protocol.

T. Srinivas,¹ C. Legendre,¹ F. Oppenheimer,¹ H. Tedesco-Silva,¹ W.-L. Luo,² P. Bernhardt,² C. Sommerer,¹ S. Chadban,¹ F. Vincenti,¹ J. Pascual.¹

6:00pm-7:00pm: A Novel, Dose-Adjusted Tacrolimus Trough Concentration (TTC) Model for Prediction and Variance Estimation.

J. Kim,¹ S. Wilson,¹ N. Undre,² S. Fei,¹ R. Kristy,¹ J. Schwartz.¹

6:00pm-7:00pm: Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts.

T. Sparkes, B. Ravichandran, O. Opara, R. Ugarte, J. Bromberg, R. Barth.

6:00pm-7:00pm: Alloimmune Quiescence in Recipients with Long-Term Surviving Kidney Grafts.

K. Brown,¹ W. Baldwin,¹ E. Poggio,² W. Braun,² R. Fairchild.¹

6:00pm-7:00pm: An Analysis of Tacrolimus XL Dosing in Obese Kidney Transplant Recipients.

N. Jasiak, J. Thielke, K. Progar, J. Chen, C. Adams, E. Benedetti, P. West-Thielke.

6:00pm-7:00pm: Anti-CD25mAb Sparing Immunosuppressive Regimen Suppressed Recurrence of Post-Transplant Focal Segmental Glomerular Sclerosis- A Single Center Experience.

H. Harada, Y. Wada, N. Fukuzawa.

6:00pm-7:00pm: Benefits of Mycophenolate Sodium Over Mycophenolate Mofetil in Renal Transplant Patients Carrying UGT1A9 Polymorphism.

N. Calvo Romero, I. Perez-Flores, A. Shabaka, M. Moreno De La Higuera, B. Rodriguez-Cubillo, J. Delgado, M. Calvo, V. Lopez De La Manzanara, A. Sanchez-Fructuoso.

6:00pm-7:00pm: CMV and BK Virus Infections in Kidney Transplant Recipients Receiving an mTORi-Based Regimen versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis.

B. Tanios,¹ S. Mallat,¹ H. Itani,¹ T. Lotfi,¹ S. Gabardi,² E. Akl,¹ J. Azzi.²

6:00pm-7:00pm: Clinical Impact of Strength and Class of Pre transplant Donor Specific Antibody on Kidney Transplant Recipient Receiving Steroid Free Maintenance Immunosupression Regimen.

O. Adebiyi, O. Simo, S. Hussain, D. Mishler, W. Goggins, T. Taber, A. Sharfuddin, M. Yaqub.

6:00pm-7:00pm: Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients.

C.-K. Oh,¹ S.-J. Kim,² K. Huh,³ S. Kim,⁴ J. Jeon,⁵ S. Han,⁶ H. Cho,⁷ Y. Kwon,⁸ S. Lee,¹ Y. Kim.³

6:00pm-7:00pm: Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).

H. Tedesco,¹ W. Irish,² K. Dharmesh,³ D. Patel,³ D. Cibrik.⁴

6:00pm-7:00pm: Comparison of Long Term Survival Outcomes for Everolimus (EVR) vs. Mycophenolic Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant.

D. Cibrik,¹ W. Irish,² K. McCague,³ D. Patel,³ H. Tedesco.⁴

6:00pm-7:00pm: Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy.

J. Yoon, S. Kang, S. Kim, C. Baeck, H. Kim, S.-K. Park.

6:00pm-7:00pm: Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.

D. Hesselink,¹ N. Shuker,¹ J. Osinga,¹ M. Clahsen -van Groningen,² J. Damman,² C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ J. Kal -van Gestel,¹ W. Weimar,¹ T. van Gelder,³ R. Bouamar.³

6:00pm-7:00pm: Conversion from Twice Daily to Once Daily Tacrolimus Improves Adherence in Kidney Transplant Recipients.

M. Levine,¹ K. Wen.²

6:00pm-7:00pm: Determinants of Successful Use of Sirolimus in Renal Transplantation.

M. Naik,¹ W. Gwinner,² W. Arns,³ E. Basic,¹⁰ K. Budde,¹ F. Diekmann,⁴ M. Fischereder,⁵ J. Goßmann,⁶ K. Heller,⁷ N. Heyne,⁸ J.-S. Jürgensen,¹ C. Morath,⁹ U. Riester.¹⁰

6:00pm-7:00pm: Early Exposure of Everolimus with and without Calcineurin Inhibitors.

C. Felipe, A. Ferreira, T. Abait, A. Bessa, P. Ruppel, L. Hiramoto, M. Ivani, H. Tedesco, J. Medina- Pestana.

6:00pm-7:00pm: Early Steroid Withdrawal and Infection in Kidney Transplant Recipients.

S. Bae, C. Durand, L. Kucirka, S. DiBrito, R. Avery, J. Garonzik Wang, D. Segev.

6:00pm-7:00pm: Effect of Everolimus on the Cardiac Function in Kidney Transplant Recipients.

K. Tsujimura,¹ M. Ota,¹ H. Ishida,² K. Tanabe.²

6:00pm-7:00pm: Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.

J. de Fijter,¹ H. Holdaas,¹ J. Sanders,¹ S. Sundar,¹ F. Bemelman,¹ P. Lopez,² G. Bader,² J. Cruzado,¹ M. van der Giet.¹

6:00pm-7:00pm: Effect of HLA-DQ Mismatch on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients: Subanalysis from the ELEVATE Study.

W. Arns,¹ J. Cruzado,¹ H. Holdaas,¹ P. Lopez,² P. Bernhardt,² G. Bader,² F. Claas,¹ M. van der Giet,¹ J. de Fijter.¹

6:00pm-7:00pm: Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients.

G. Chen, C. Wang, Z. Wu, C. Wang, J. Qiu, L. Chen.

6:00pm-7:00pm: Evaluation of the Conversion from Brand Name to Generic Immunosuppression in Hospitalized Organ Transplant Recipients.

L. DeZotell,¹ K. Blunck,¹ J. Guy,¹ M. Woods,¹ M. Reffett,² J. Terrell,² A. Palermo,² K. Gosch,³ L. Cummings.⁴

6:00pm-7:00pm: Everolimus Does Not Increase Risk of Delayed Graft Function or Prolong Duration of Dialysis in Renal Transplantation.

F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶

6:00pm-7:00pm: Evolution of CCR4highCD4+ Subpopulations in Renal Graft Blood After Steroid Withdrawal: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results.

J. Alonso-Titos,¹ P. Ruiz-Esteban,¹ E. Palma,¹ A. Caballero,² E. Sola,¹ M. Cabello,¹ T. Vazquez,¹ A. Duarte,¹ C. Jironda,¹ D. Hernandez.¹

6:00pm-7:00pm: Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated with Belatacept.

W. Kitchens, A. Farris, S. Pastan, T. Pearson, C. Larsen, A. Adams.

6:00pm-7:00pm: High Risk Renal Transplant Recipients on Steroid Free Immunosupression Regimen. Indiana University Experience.

O. Adebiyi, S. Hussain, D. Mishler, W. Goggins, M. Yaqub, T. Taber, A. Sharfuddin.

6:00pm-7:00pm: Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).

B. Burrell,¹ J. Bromberg,² C. Hartono,³ A. Posselt,⁴ A. Naji,⁵ D. Kaufman,⁶ R. Redfield III,⁶ S. Kanaparthi,¹ D. Ikle,⁷ K. Much,⁷ N. Bridges,⁸ L. Sun,¹ A. Priore,⁸ M. DesMarais,¹ K. Crisalli,⁹ S. Chandran,¹ J. Markmann.⁹

6:00pm-7:00pm: Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.

J. Howell,¹ R. Pollock,² J. Schwartz.³

6:00pm-7:00pm: Impact of Polymorphisms of UGT 1 A9 on the Prognosis of Renal Transplant Patients. Association with Digestive Tumors.

N. Calvo, I. Perez-Flores, A. Shabaka, M. Moreno, B. Rodriguez-Cubillo, J. Delgado, M. Calvo, A. Sanchez-Fructuoso.

6:00pm-7:00pm: Influence of Tacrolimus Metabolism Rate on Patients' Survival After Renal Transplantation.

G. Thölking, J. Steinke, K. Schuette-Nuetgen, H. Pavenstädt, B. Suwelack, S. Reuter.

6:00pm-7:00pm: Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.

G. Gu, H. Hang, Q. Xia.

6:00pm-7:00pm: More Than Renal Function: Use of Belatacept to Improve Drug Toxicities.

E. Cohen,¹ B. Knight,³ W. Asch.²

6:00pm-7:00pm: Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.

K. Unagami,¹ M. Okumi,² T. Hirai,² D. Toki,³ H. Shirakawa,⁴ T. Shimizu,² K. Omoto,⁵ M. Inui,³ H. Ishida,² K. Nitta,¹ K. Tanabe.²

6:00pm-7:00pm: One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.

Y. Hidaka,¹ S. Yamanaga,¹ M. Toyoda,¹ S. Narumi,² Y. Watarai,² T. Kobayashi.³

6:00pm-7:00pm: Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.

Y. Watarai,¹ S. Narumi,¹ M. Okada,¹ R. Kimura,¹ K. Hatazoe,¹ K. Futamura,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ T. Kobayashi.²

6:00pm-7:00pm: Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Dosing.

D. Hesselink,¹ L. Andrews,² B. de Winter,² J. Tang,³ N. Shuker,² R. Bouamar,² R. van Schaik,⁴ B. Koch,² T. Van Gelder.¹

6:00pm-7:00pm: Personalized Tacrolimus (TAC) Dosing Using Genetic Variants in Caucasian Kidney Transplant (Tx) Recipients.

D. Margraf,¹ R. Brundage,¹ D. Schladt,² W. Guan,³ B. Wu,³ R. Remmel,⁴ C. Dorr,^2,7 D. Berglund,¹ R. Mannon,⁵ A. Matas,⁶ W. Oetting,¹ A. Israni,^2,7 P. Jacobson,¹ For the DeKAF Genomics Investigators.

6:00pm-7:00pm: Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.

P. Trevillian,^1,2,3 M. Heer,^1,2 S. Ainsworth,¹ A. Hibberd.^1,2,3

6:00pm-7:00pm: Pre Transplant Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipient on Steroid Free Maintenance Immunosupression Regimen.

O. Adebiyi,¹ A. Sharfuddin,² M. Yaqub,¹ S. Hussain,¹ D. Mishler,¹ A. Sharfuddin,¹ W. Goggins,¹ T. Taber.¹

6:00pm-7:00pm: Prevalence of CYP3A Genomic Variances and Impact on Tacrolimus Dosing Requirements in Kidney Transplant Recipients in Eastern North Carolina.

T. Asempa,¹ S. Hudson,² L. Rebellato,² A. Maldonado.¹

6:00pm-7:00pm: Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study.

K. Yoshida,¹ Y. Watarai,² K. Nakagawa,³ O. Kamisawa.⁴

6:00pm-7:00pm: Risks Associated with Recombinant IL2 Therapy in Renal Transplantation.

M. McGrath, S. Tripathi, A. Chandraker.

6:00pm-7:00pm: Single-Center, Prospective, Open Label Pilot Study to Investigate the Effectiveness of Everolimus Associated with Mycophenolic Acid and Prednisone in Adult Patients Submitted to an Allograft Renal Transplant with Calcineurin Inhibitor Withdrawl on Week 16th.

L. Giordano,^1,2 M. Lasmar,^1,2 H. Vianna,^1,2 E. Lasmar.^1,2

6:00pm-7:00pm: Steroid Free Maintenance Immunosupression in Kidney Transplantation: Indiana University Experience.

S. Hussain, T. Taber, A. Sharfuddin, M. Yaqub, W. Goggins, D. Mishler, O. Adebiyi.

6:00pm-7:00pm: Steroid Withdrawal Using Everolimus in Maintenance Kidney Transplant Recipients with Post-Transplant Diabetes Mellitus.

K. Nanmoku, A. Kurosawa, T. Kubo, T. Shinzato, T. Shimizu, T. Kimura, T. Yagisawa.

6:00pm-7:00pm: Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?

K. Jayant,¹ I. Reccia,² J. Walton,¹ A. Sharma,³ A. Halawa.¹

6:00pm-7:00pm: Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients.

L. Qu, Z. Xie, H. Huang, H. Jiang, J. Chen, H. Jiang, H. Jiang, J. Chen, J. Chen, J. Chen.

6:00pm-7:00pm: Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.

S. Seibert,¹ D. Schladt,² B. Wu,³ W. Guan,³ C. Dorr,^2,7 D. Berglund,¹ R. Remmel,⁴ A. Matas,⁵ R. Mannon,⁶ A. Israni,^2,7 W. Oetting,¹ P. Jacobson,¹ For the DeKAF Genomics Investigators.

6:00pm-7:00pm: Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.

S.-Y. Kim,¹ J. Oh,² S. Yun,² I.-J. Jang,² S.-I. Min,¹ W. Cho,¹ S. Cho,¹ S. Ahn,¹ S.-K. Min,¹ J. Ha.¹

6:00pm-7:00pm: The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.

A. Hart,^1,2 S. Gustafson,² A. Wey,² N. Hadley,² A. Israni.²

6:00pm-7:00pm: The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.

S. Rhazouani,^1,4 S. Anwar,² D. Brennan,¹ K. Lentine,³ K. Venkatachalam,¹ A. Malone,¹ T. Alhamad.¹

« View all sessions from the 2017 American Transplant Congress